Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study
Arthritis & Rheumatology · 2024-07 · 76 (7) · 1120-1129
DOI: 10.1002/art.42817 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Arthritis & Rheumatology, online erschienen am 22.02.2024. Verfasst von Omer Karadag und 30 weiteren Autor:innen. Beteiligte Einrichtung: Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Polyarteritis Nodosa. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute for Health Research Cambridge Biomedical Research Centre, Intramural NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Objective
We describe the demographics, clinical features, disease course, and survival of polyarteritis nodosa (PAN) through an international collaboration (GLOBAL‐PAN).
Methods
Patients with PAN were recruited between 1990 and 2020 from observational cohorts of nine countries across Europe, Japan, and North America. Eligibility was retrospectively defined using the European Medicines Agency classification algorithm. Patients with PAN related to hepatitis B virus (n = 12) and two monogenic diseases mimicking PAN, deficiency of adenosine deaminase 2 enzyme (n = 16) or familial Mediterranean fever (n = 11), were excluded. Data regarding organ involvement, relapse, disease‐related damage, and survival were analyzed.
Results
Three hundred fifty‐eight patients (female:male ratio 174:184), including those with systemic PAN (sPAN, n = 282) and cutaneous PAN (n = 76), were included. Twenty‐five were pediatric onset. Mean ± SD age at diagnosis was 44.3 ± 18.1 years. Constitutional symptoms (71.5%), cutaneous involvement (70.5%), musculoskeletal findings (69.1%), and neurologic features (48.0%) were common manifestations. Among patients with sPAN, gastrointestinal involvement and proteinuria over 400 mg/day were reported in 52.2% and 11.2%, respectively. During a median (interquartile range) 59.6 (99.5) months of follow‐up, relapse occurred in 48.5% of patients. One, 5‐ and 10‐year survival rates for sPAN were 97.1%, 94.0%, and 89.0%, respectively. Predictors of death for sPAN included age ≥65 years at diagnosis, serum creatinine at diagnosis >140 μmol/L, gastrointestinal manifestations, and central nervous system (CNS) involvement.
Conclusion
The spectrum of PAN remains a complex, multifaceted disease. Relapse is common. Age ≥65 years and serum creatinine >140 μmol/L at diagnosis, as well as gastrointestinal and CNS involvement, are independent predictors of death in sPAN. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Hacettepe University, Ankara, Turkey.
- Skåne University Hospital, Lund, Sweden, and University of Cambridge, Cambridge, UK.
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
- Mount Sinai Hospital, Toronto, Ontario, Canada.
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
- Università di Pavia, Pavia, Italy.
ORCID-Profile: Omer Karadag, Ertugrul Cagri Bolek, Gizem Ayan, Aladdin J Mohammad, Peter C Grayson, Christian Pagnoux, Eduardo Martín-Nares, Sara Monti, Yoshiyuki Abe, Fatma Alibaz-Oner, David Cuthbertson, Haner Direskeneli, Nader A Khalidi, Carol A McAlear, Kenneth J Warrington, Alojzija Hocevar, Andrea Hinojosa-Azaola, Seza Ozen, David Jayne, Peter A Merkel
Förderung
- National Institute for Health Research Cambridge Biomedical Research Centre
- Intramural NIH HHS
- NCRR NIH HHS
- National Center for Advancing Translational Science, the National Institute of Arthritis and Musculoskeletal and Skin Diseases
- NIAMS NIH HHS
- NIHR Cambridge Biomedical Research Centre
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Center for Research Resources
Zitieren
APA
Karadag, O., Bolek, E. C., Ayan, G., Mohammad, A. J., Grayson, P. C., Pagnoux, C., Martín-Nares, E., Monti, S., Abe, Y., Alberici, F., Alibaz-Oner, F., Cuthbertson, D., Dagna, L., Direskeneli, H., Khalidi, N. A., Koening, C., Langford, C. A., McAlear, C. A., Monach, P. A., …, & GLOBAL‐PAN Collaborators (2024). Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study. Arthritis & Rheumatology, 76(7), 1120-1129. https://doi.org/10.1002/art.42817
Vancouver
Karadag O, Bolek EC, Ayan G, Mohammad AJ, Grayson PC, Pagnoux C, et al. Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study. Arthritis & Rheumatology. 2024;76(7):1120-1129. doi:10.1002/art.42817
BibTeX
@article{Karadag2024,
author = {Karadag, Omer and Bolek, Ertugrul Cagri and Ayan, Gizem and Mohammad, Aladdin J and Grayson, Peter C and Pagnoux, Christian and Martín-Nares, Eduardo and Monti, Sara and Abe, Yoshiyuki and Alberici, Federico and Alibaz-Oner, Fatma and Cuthbertson, David and Dagna, Lorenzo and Direskeneli, Haner and Khalidi, Nader A and Koening, Curry and Langford, Carol A and McAlear, Carol A and Monach, Paul A and Moroni, Luca and Padoan, Roberto and Seo, Phillip and Warrington, Kenneth J and Hocevar, Alojzija and Hinojosa-Azaola, Andrea and Furuta, Shunsuke and Emmi, Giacomo and Ozen, Seza and Jayne, David and Merkel, Peter A and GLOBAL‐PAN Collaborators, GLOBAL‐PAN Collaborators},
title = {Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study},
journal = {Arthritis & Rheumatology},
year = {2024},
volume = {76},
number = {7},
pages = {1120--1129},
doi = {10.1002/art.42817}
}
EUVIMED